# US 2016/0256567 A1 · Compositions and methods for delivering messenger rna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256567 A1
- Document ID: US20160256567A1
- Status: Published application
- Kind: A1
- Application number: 15/153,211
- Filed: 2016-05-12
- Published: 2016-09-08
- Earliest claimed: 2013-07-23
- Assignees: Protiva Biotherapeutics, Inc.
- Applicants: Protiva Biotherapeutics, Inc.
- Inventors: James HEYES; Lorne R. PALMER; Stephen P. REID; Edward D. YAWORSKI; Ian MACLACHLAN; Mark WOOD; Alan D. MARTIN
- Web page: https://patentgrep.com/patent/US20160256567A1

## CPC

- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/145: {with organic compounds}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 229/12: to carbon atoms of acyclic carbon skeletons
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provided cationic lipids that are useful for preparing the compositions of the invention.

## Claims

### Claim 1

A lipid particle comprising a cationic trialkyl lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle.

### Claim 2 (depends on 1)

The lipid particle of claim 1, wherein the non-cationic lipid is selected from a PEG-lipid conjugate and a phospholipid.

### Claim 3 (depends on 1)

The lipid particle of claim 1, wherein the lipid particle further comprises cholesterol.

### Claim 4 (depends on 2)

The lipid particle of claim 2, wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.

### Claim 5 (depends on 2)

The lipid particle of claim 2, wherein the PEG-lipid conjugate is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.

### Claim 6 (depends on 2)

The lipid particle of claim 2, wherein the PEG-lipid conjugate is a PEG-DAA conjugate.

### Claim 7 (depends on 6)

The lipid particle of claim 6, wherein the PEG-DAA conjugate is selected from the group consisting of a PEG-didecyloxypropyl (C10) conjugate, a PEG-dilauryloxypropyl (C12) conjugate, a PEG-dimyristyloxypropyl (C14) conjugate, a PEG-dipalmityloxypropyl (C16) conjugate, a PEG-distearyloxypropyl (C18) conjugate, and a mixture thereof.

### Claim 8 (depends on 2)

The lipid particle of claim 2, wherein the PEG-lipid conjugate is PEG-DMA or PEG-DSA.

### Claim 9 (depends on 1)

The lipid particle of claim 1, wherein the mRNA is fully encapsulated in the particle.

### Claim 10 (depends on 1)

The lipid particle of claim 1, wherein the particle has a lipid:mRNA mass ratio of from about 9:1 to about 20:1.

### Claim 11 (depends on 1)

The lipid particle of claim 1, wherein the cationic trialkyl lipid comprises from about 50 mol % to about 65 mol % of the total lipid present in the particle.

### Claim 12 (depends on 2)

The lipid particle of claim 2, wherein the phospholipid comprises from about 4 mol % to about 15 mol % of the total lipid present in the particle.

### Claim 13 (depends on 3)

The lipid particle of claim 3, wherein the cholesterol comprises from about 30 mol % to about 40 mol % of the total lipid present in the particle.

### Claim 14 (depends on 2)

The lipid particle of claim 2, wherein the PEG-lipid conjugate comprises from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.

### Claim 15 (depends on 1)

The lipid particle of claim 1, wherein the mRNA is chemically modified.

### Claim 16 (depends on 1)

The lipid particle of claim 1, wherein the particle is spherical.

### Claim 17 (depends on 1)

The lipid particle of claim 1, wherein the lipid particle is non-spherical.

### Claim 18 (depends on 1)

The lipid particle of claim 1, wherein the lipid particle comprises an electron dense core and wherein the mRNA is located within the electron dense core.

### Claim 19 (depends on 18)

The lipid particle of claim 18, wherein the electron dense core comprises an aqueous component and a lipid component, wherein the amount of the aqueous component is less than the amount of the lipid component.

### Claim 20 (depends on 1)

The lipid particle of claim 1, comprising a multiplicity of mRNA molecules that are encapsulated within the lipid particle.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a lipid particle of claim 1 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 1)

A composition comprising a population of lipid particles as described in claim 1.
